Table 3 |
||||
|
Estimated risk of death or chronic disability per 1 million population resulting from L. loa encephalopathy following mass treatment with Mectizan®, under conditions of: 1) no mass treatment; 2) mass treatment with no risk reduction strategy; and 3) mass treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 to reduce risk of L. loa encephalopathy. Four scenarios are considered based on high and low prevalence of loiasis and onchocerciasis, respectively (defined in the Appendix - see 1). |
||||
|
Loiasis Prevalence |
High |
High |
Low |
Low |
|
Onchocerciasis Prevalence |
High |
Low |
High |
Low |
|
|
||||
|
No Mectizan® treatment |
0 |
0 |
0 |
0 |
|
Mectizan® treatment |
||||
|
No risk-reduction strategy |
85.1 |
85.1 |
26.0 |
26.0 |
|
REA |
5.1 |
3.4 |
0.5 |
0.3 |
|
RAPLOA-40 |
12.9 |
12.9 |
2.0 |
2.0 |
|
RAPLOA-20 |
5.6 |
5.6 |
0.6 |
0.6 |
|
REA/RAPLOA-40 |
12.4 |
11.0 |
2.0 |
1.9 |
|
|
||||
|
Addiss et al. Filaria Journal 2003 2(Suppl 1):S9 |
||||
